GW Pharmaceuticals (GW Pharmaceuticals) EV-to-FCF : -130.74 (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is GW Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GW Pharmaceuticals's Enterprise Value is $6,019.5 Mil. GW Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2021 was $-46.0 Mil. Therefore, GW Pharmaceuticals's EV-to-FCF for today is -130.74.

The historical rank and industry rank for GW Pharmaceuticals's EV-to-FCF or its related term are showing as below:

GWPRF' s EV-to-FCF Range Over the Past 10 Years
Min: -138.98 Med: -16.48 Max: 81.56
Current: -130.74

During the past 13 years, the highest EV-to-FCF of GW Pharmaceuticals was 81.56. The lowest was -138.98. And the median was -16.48.

GWPRF's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 22.78 vs GWPRF: -130.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), GW Pharmaceuticals's stock price is $17.00. GW Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.180. Therefore, GW Pharmaceuticals's PE Ratio for today is At Loss.

GW Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for GW Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals EV-to-FCF Chart

GW Pharmaceuticals Annual Data

Trend

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

EV-to-FCF

Get a 7-Day Free Trial

-21.39

-14.31

-17.68

-16.48

-53.30

GW Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EV-to-FCF	Get a 7-Day Free Trial															-17.62	-30.80	-27.51	-53.30	-132.01

Competitive Comparison of GW Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GW Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's EV-to-FCF falls into.

GW Pharmaceuticals EV-to-FCF Calculation

GW Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF	=	Enterprise Value (Today)	/	Free Cash Flow (TTM)
	=	6019.506	/	-46.041
	=	-130.74

GW Pharmaceuticals's current Enterprise Value is $6,019.5 Mil.
GW Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.0 Mil.

GW Pharmaceuticals (OTCPK:GWPRF) EV-to-FCF Explanation

GW Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	17.00	/	-0.180
	=	At Loss

GW Pharmaceuticals's share price for today is $17.00.
GW Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.180.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

GW Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (OTCPK:GWPRF) » Definitions » EV-to-FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ

Website

http://www.gwpharm.com

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.